1. Home
  2. BMA vs TLX Comparison

BMA vs TLX Comparison

Compare BMA & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMA
  • TLX
  • Stock Information
  • Founded
  • BMA 1966
  • TLX 2015
  • Country
  • BMA Argentina
  • TLX Australia
  • Employees
  • BMA N/A
  • TLX N/A
  • Industry
  • BMA Commercial Banks
  • TLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BMA Finance
  • TLX Health Care
  • Exchange
  • BMA Nasdaq
  • TLX Nasdaq
  • Market Cap
  • BMA 6.3B
  • TLX 6.0B
  • IPO Year
  • BMA 2006
  • TLX N/A
  • Fundamental
  • Price
  • BMA $76.85
  • TLX $16.21
  • Analyst Decision
  • BMA Hold
  • TLX Strong Buy
  • Analyst Count
  • BMA 3
  • TLX 1
  • Target Price
  • BMA $50.83
  • TLX $22.00
  • AVG Volume (30 Days)
  • BMA 269.7K
  • TLX 30.1K
  • Earning Date
  • BMA 05-21-2025
  • TLX 01-01-0001
  • Dividend Yield
  • BMA 6.91%
  • TLX N/A
  • EPS Growth
  • BMA N/A
  • TLX 798.14
  • EPS
  • BMA 0.49
  • TLX 0.09
  • Revenue
  • BMA $4,443,772,797.00
  • TLX $484,687,790.00
  • Revenue This Year
  • BMA N/A
  • TLX N/A
  • Revenue Next Year
  • BMA $5.76
  • TLX N/A
  • P/E Ratio
  • BMA $19.08
  • TLX $181.03
  • Revenue Growth
  • BMA N/A
  • TLX 55.85
  • 52 Week Low
  • BMA $42.23
  • TLX $14.01
  • 52 Week High
  • BMA $118.42
  • TLX $30.36
  • Technical
  • Relative Strength Index (RSI)
  • BMA 40.79
  • TLX N/A
  • Support Level
  • BMA $73.05
  • TLX N/A
  • Resistance Level
  • BMA $77.89
  • TLX N/A
  • Average True Range (ATR)
  • BMA 3.82
  • TLX 0.00
  • MACD
  • BMA -0.14
  • TLX 0.00
  • Stochastic Oscillator
  • BMA 26.93
  • TLX 0.00

About BMA Banco Macro S.A. ADR (representing Ten Class B)

Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.

About TLX Telix Pharmaceuticals Limited American Depositary Shares

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Share on Social Networks: